Regeneron’s aflibercept (Eylea) has been approved by the FDA for a prefilled syringe (PFS) presentation. The 2-mg, single-dose, PFS will offer the greater ease of use less preparation than the vial presentation of the drug used to treat a range of eye disorders.
Regeneron’s aflibercept (Eylea) has been approved by the FDA for a prefilled syringe (PFS) presentation. The 2-mg, single-dose, PFS will offer the greater ease of use less preparation than the vial presentation of the drug used to treat a range of eye disorders.
"With [8] pivotal phase 3 trials and millions of injections used around the world, Eylea sets a high bar for visual acuity and safety across multiple retinal diseases, including wet age-related macular degeneration and diabetic eye diseases," said George D. Yancopoulos, MD, PhD, president and chief scientific officer of Regeneron, in a statement. "This approval may help doctors more conveniently and efficiently deliver Eylea to appropriate patients."
The approval comes just 3 months after Regeneron also received approval for the drug to treat all stages of diabetic retinopathy. The regulatory decision made aflibercept the only anti-vascular endothelial growth factor (anti-VEGF) therapy approved for 2 dosing regimens in this indication: every 8 weeks or every 4 weeks.
Both approvals coincide with increased pressure on Regeneron to defend its market share for the blockbuster drug. One challenge could come from Novartis’ innovator biologic, RTH258, brolucizumab. This novel biologic is a humanized single-chain antibody fragment with enhanced tissue penetration and rapid clearance from systemic circulation, and the agent has been shown to be more effective in reducing disease activity and retinal fluid than aflibercept.
Aflibercept is also the target of multiple biosimilar development programs; Momenta and Mylan entered a phase 3 pivotal trial of a biosimilar aflibercept candidate in 2018, and Coherus BioSciences is also advancing an aflibercept candidate as well as a ranibizumab candidate, referencing another anti-VEGF agent, Lucentis. Xbrane Biopharma and Samsung Bioepis are also both working on biosimilars of ranibizumab.
Finally, another anti-VEGF agent, bevacizumab, is widely used off-label in treating eye disorders, and has 1 recently launched biosimilar available in the United States: Amgen’s Mvasi.
Revolutionizing Biopharmaceuticals: The EU's Biosimilar Success and Remaining Challenges
October 16th 2024The European Union's (EU) approach to biosimilars has revolutionized the biopharmaceutical market by driving innovation, lowering costs, and increasing adoption; however, there remains a need for more education, real-world evidence, and efforts to address challenges to enhance patient access and affordability.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
Samsung Bioepis Report Showcases Adalimumab Biosimilar Growth in Market Share
October 11th 2024Adalimumab biosimilars have seen a significant increase in market share, from 2% in early 2024 to 22%, as payers and pharmacy benefit managers begin to prioritize these biosimilars over the reference product, Humira.
Sandoz Report: A Unified Approach to Overcoming Drug Shortages
October 10th 2024A report from Sandoz emphasizes the need for collaboration among stakeholders to eliminate drug shortages impacting over 90% of hospital systems in the US, recommending policy changes and actions to address the ongoing issue, which has caused treatment delays and increased costs.